Kate Kimes, DO
Dermatology · Ft Wainwright, AKNPI 1750772018
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.5% of the total across 82 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by AbbVie at 35.9% of the total.
Across 82 payments — averaging $20.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$594
- Johnson & Johnson$294
- Regeneron Healthcare Solutions, Inc.$150
- Lilly USA, LLC$125
- UCB, Inc.$117
- Sanofi$117
- plus $259 from 5 others
What the payments were for
- Food & beverage$1,54894%
- Education$1076%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 34 | $594 |
| Johnson & Johnson | 14 | $294 |
| Regeneron Healthcare Solutions, Inc. | 5 | $150 |
| Lilly USA, LLC | 6 | $125 |
| UCB, Inc. | 5 | $117 |
| Sanofi | 5 | $117 |
| Galderma Laboratories, L.p. | 5 | $99 |
| Novartis | 2 | $50 |
| Arcutis Biotherapeutics, Inc. | 3 | $46 |
| LEO Pharma Inc. | 2 | $41 |
| Organogenesis Inc. | 1 | $23 |
How this compares
$1,655 in reported general payments places this provider in the 65th percentile of 22 dermatology providers in Alaska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Clobetasol Propionate | 196 | $7,676 |
| Tacrolimus | 25 | $2,532 |
| Fluorouracil | 30 | $2,399 |
| Clindamycin Phosphate | 72 | $1,700 |
| Ketoconazole | 95 | $1,435 |
| Desonide | 21 | $1,029 |
| Metronidazole | 23 | $962 |
| Triamcinolone Acetonide | 115 | $926 |
| Doxycycline Hyclate | 29 | $743 |
| Mometasone Furoate | 35 | $625 |
| Fluocinolone Acetonide Oil | 12 | $442 |
| Betamethasone Valerate | 14 | $352 |
| Ciclopirox | 12 | $338 |
| Nystatin | 33 | $333 |
| Mupirocin | 23 | $180 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Ft Wainwright
- McKay FrandsenFt Wainwright$232
- Robert MorelandAnchorage$18K
- Michael MichenerAnchorage$14K
- Jayne FortsonAnchorage$13K
- Stephanie McLeishAnchorage$8K
- Blake GallerWasilla$7K
- Kimberly WonderlichFairbanks$2K
- Courtney BagayokoAnchorage$2K
- Janine MillerAnchorage$1K
- Roger ThurmondFairbanks$665
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.